Today: 8 June 2026
Browse Category

XETRA:MRK 27 June 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.
9 January 2026
···
$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears

German Stock Market Today, 13 Nov 2025: DAX Closes 1.39% Lower at 24,041 as Siemens Slumps; Merck Rises, Allianz Lifts Guidance

Germany’s DAX fell 1.39% to 24,041.62 on Thursday, its steepest drop since October 2025, after Siemens shares plunged 9.4% on weaker-than-expected earnings and plans to spin off most of its Healthineers stake. The broader STOXX 600 closed down 0.6%. Merck KGaA and Renk rose, while Deutsche Telekom and BASF posted corporate updates. Investors shifted focus to upcoming U.S. economic data.
13 November 2025
·····
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • AI Companies Expand Rapidly Into Competitors' Markets
    June 8, 2026, 4:17 AM EDT. AI industry leaders are swiftly entering each other's markets, blurring traditional boundaries. This expansion highlights intense competition and growing demand for AI solutions across sectors. Companies are diversifying product lines to capture larger market shares. Market analysts note increased cross-sector collaboration and rivalry, pushing innovation. Investors watch closely as the race to dominate AI spaces accelerates. This trend signals a dynamic shift in the technology landscape, emphasizing the strategic importance of AI in future business growth.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

8 June 2026
LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 8, 2026, 4:18 AM EDT AI Companies Expand Rapidly Into Competitors' Markets June 8, 2026, 4:17 AM EDT. AI industry leaders are swiftly entering each other’s markets, blurring traditional boundaries. This expansion highlights intense competition and growing demand for AI solutions across sectors. Companies are diversifying product lines to capture larger market shares. Market analysts note increased cross-sector collaboration and rivalry, pushing innovation. Investors watch closely as the race to dominate AI spaces accelerates. This trend signals a dynamic shift in the technology landscape, emphasizing the strategic importance of AI
Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
Go toTop